AMGN

3 Reasons Not to Lose Faith in Amgen, Inc. (AMGN)

Amgen (AMGN) may have missed the mark with one trial, but that's not unusual or alarming within the world of biopharma. More

77 Actions to Take on Today’s Dip

It pays to stay on top of the latest profit opportunities, and today's Portfolio Grader blog post is a great place to start More

10 Biotechnology Stocks to Buy Now

The grades of 10 Biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating. More

Amgen, Inc (AMGN) – Amgen Stock Is a Powerhouse

Biotechs such as Amgen stock have been riding high for more than a month. AMGN in particular looks promising for new money. More

Amgen, Inc.: AMGN Stock May Be Prepping for a Surge

A breakout, relative strength and bid options premiums point to a bullish earnings reaction in AMGN this week. More

Amgen, Inc. (AMGN) Stock: Good Fundamentals, Good Yield, Good Opportunity

A combination of dividend, fundamental, technical and implied volatility analysis has uncovered a solid opportunity in AMGN. More

IBB: The iShares NASDAQ Biotechnology Index (ETF) Is Still a Buy

Even if Hillary Clinton becomes the next POTUS, biotech stocks won't sink into oblivion -- that's enough reason to buy the IBB ETF. More

Recent Articles